Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts

Key Points

• Analysts give Inhibikase Therapeutics (NASDAQ:IKT) a consensus Buy rating from six firms, with a breakdown of four strong-buy, one hold and one sell.
• Shares were up 3.6%, opening at $2.02; the stock trades in a 52-week range of $1.33–$2.58, has a 50-day moving average of $1.78, a market cap of $151.86 million and a negative P/E of -5.18.
• Inhibikase is a clinical-stage pharma developing IkT-148009 (an Abelson tyrosine kinase inhibitor) for Parkinson’s disease and related GI symptoms, plus IkT-001Pro, a prodrug of imatinib, in preclinical development.

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a strong buy rating on the company.

Several equities analysts recently issued reports on the company. Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a research note on Monday, February 23rd. Zacks Research raised Inhibikase Therapeutics to a "hold" rating in a research report on Tuesday, December 2nd. LADENBURG THALM/SH SH upgraded shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Friday, December 26th.

Inhibikase Therapeutics Stock Up 3.6%

NASDAQ:IKT opened at $2.02 on Thursday. Inhibikase Therapeutics has a 52 week low of $1.33 and a 52 week high of $2.58. The stock's fifty day moving average price is $1.78. The firm has a market capitalization of $151.86 million, a PE ratio of -5.18 and a beta of 0.76.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.